Myocarditis and myasthenia gravis by combined nivolumab and ipilimumab immunotherapy for renal cell carcinoma: A case report of successful management

Ipilimumab plus nivolumab (Ipi/Nivo) has revolutionized advanced renal cell carcinoma (RCC) treatment. However, it encompassed fatal immune-related adverse events (irAEs). Myocarditis with concomitant myasthenia gravis (MG) has a mortality rate of 50%, and a high dose of methylprednisolone (mPSL) sh...

Descripción completa

Detalles Bibliográficos
Autores principales: Yanase, Takahiro, Moritoki, Yoshinobu, Kondo, Hajime, Ueyama, Daigo, Akita, Hidetoshi, Yasui, Takahiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7726655/
https://www.ncbi.nlm.nih.gov/pubmed/33318935
http://dx.doi.org/10.1016/j.eucr.2020.101508

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7726655/
https://www.ncbi.nlm.nih.gov/pubmed/33318935
http://dx.doi.org/10.1016/j.eucr.2020.101508

Ejemplares similares